Migraine headaches are the most frequent type of incapacitating headache and one of the most common reasons for consultation in neurology. However, these headaches have historically been poorly understood in terms of natural history, pathophysiology and prognosis. This unsatisfactory state of affairs had important consequences for the diagnosis and treatment of migraine, which have been frequently inadequate. Indeed, the first rational classification of headache semiology, providing an unambiguous definition of migraine was established relatively recently by the International Headache Society in 1988 ([@b89-tcrm-4-1061]) (revised in 2004 \[[@b90-tcrm-4-1061]\]). This provides a framework for the standardized diagnosis of migraine.

For this reason, there is little available data on long-term disease course from natural history cohorts which have used this diagnosis classification. In particular, although headache relief treatments, often with over-the-counter analgesic drugs, are widely used, the long-term management of migraine, involving prophylactic treatments and the implementation of strategies to prevent headache evolution to more severe disease and to promote remission, has been explored relatively little. This situation has changed somewhat over recent years with the introduction of standardized guidelines for the diagnosis and treatment of migraine headaches. Moreover, the introduction of triptans as a specific treatment for relief of migraine headaches has stimulated much research into the biology of migraine, leading to a better understanding of its pathophysiology. This articles reviews recent developments in our understanding of migraine and their consequences for improved management of migraine as a chronic disease.

Natural history of migraine
===========================

Migraine headache generally presents for the first time during adolescence, with a lower mean age of onset in males than in females ([@b245-tcrm-4-1061]). However, migraine does occur in younger children ([@b1-tcrm-4-1061]; [@b7-tcrm-4-1061]) and may be under-diagnosed due to difficulties in assessing accurately symptomatology in this population.

There have been few longitudinal studies investigating long-term outcome of migraine headache. However, given that the prevalence of migraine decreases with age, it can be expected that, in many cases, these headaches resolve spontaneously. Two recent studies have evaluated long-term outcome in larger populations whose original migraine diagnosis was established using the IHS criteria. The first study followed up 549 of 740 subjects originally diagnosed with episodic headaches in 1989 ([@b149-tcrm-4-1061]). Twelve years after the original diagnosis, 42% of subjects were in remission, 38% had less frequent headaches and 20% had more frequent headaches. Poor outcome was associated with high migraine frequency at baseline and age at onset younger than 20 years. For tension-type headache, remission was observed in 45% of subjects and transformation into a chronic tension-type headache was reported in 16%. The second study evaluated 1250 of 2051 subjects originally identified in 2003, of whom 398 fulfilled diagnostic criteria for migraine ([@b175-tcrm-4-1061]). Ten years later, 37% stilled fulfilled these criteria, whereas 36% now fulfilled diagnostic criteria for migrainous disorder and 18% for other episodic headache types, the remainder being in complete remission. Remission or evolution to a less severe headache was more frequent in men and in older subjects.

Chronic headache presentations
==============================

These longitudinal studies identify a minority of subjects whose condition deteriorates with time, notably with an increased frequency of headaches. This corresponds to the notion of transformed migraine ([@b164-tcrm-4-1061]) or chronic daily headache. Many of these headaches may be iatrogenic and high levels of analgesic drug use have been described in up to three-quarters of cases ([@b159-tcrm-4-1061]) and are associated with a risk of transformation ([@b257-tcrm-4-1061]; [@b52-tcrm-4-1061]). Although analgesic drugs have been implicated most frequently in the development of chronic daily headaches, recent studies suggest that use of specific acute migraine treatments (triptans) may also lead to transformation of migraine ([@b133-tcrm-4-1061]). High caffeine use has also been described as a risk factor for transformation ([@b203-tcrm-4-1061]). Psychiatric comorbidity, notable depression, may also be associated with an increased risk of transformation ([@b159-tcrm-4-1061]; [@b248-tcrm-4-1061]).

In addition, tension-type headaches may also evolve into a chronic form. Chronic tension-type headaches, as defined in the IHS classification, occur with a frequency of over 180 days per year and are distinguished from transformed migraine (or chronic daily headache with migrainous features) by their characteristic symptom presentation (steady rather than pulsatile pain, bilateral rather than unilateral, etc). Some characteristic features of migraine, such as nausea, are less prevalent in subjects with chronic daily headache than in those with classical migraine headache ([@b219-tcrm-4-1061]; [@b158-tcrm-4-1061]; [@b128-tcrm-4-1061]). The overall prevalence of chronic daily headache in the general population is around 4% ([@b248-tcrm-4-1061]; [@b202-tcrm-4-1061]; [@b27-tcrm-4-1061]; [@b128-tcrm-4-1061]), with most studies reporting chronic tension-type headache to be more frequent than transformed migraine. Individuals presenting with these headache types represent a large segment of the population consulting specialist headache centres. Chronic daily headaches often remit spontaneously, and a one-year remission rate of 14% has been estimated from a general population sample ([@b204-tcrm-4-1061]). Factors associated with a poor prognosis of chronic daily headache include older age, long duration of chronic headaches and medication overuse ([@b248-tcrm-4-1061]; [@b145-tcrm-4-1061]).

Consequences for treatment
==========================

The long-term outcome of migraine can thus be variable ([Figure 1](#f1-tcrm-4-1061){ref-type="fig"}) and it is an important objective of therapy to ensure a favorable outcome (remission). This raises a number of important questions. Classical migraine can be managed effectively with acute or prophylactic treatments (see below) although analgesic drugs should be avoided as headache relief medication in order to reduce the risk of transformation to a chronic headache type. Certain of these drugs may be acquired over the counter and used as self-medication, and it is important to identify and discourage such habits in patients consulting for migraine headache. In patients whose headaches have already transformed into a chronic presentation, medication withdrawal can in many cases be sufficient to promote remission ([@b135-tcrm-4-1061]; [@b108-tcrm-4-1061]).

Migrainous disorder can be considered as a 'mild' form of classical migraine and clinical experience suggests that these headaches respond to the same relief medications as the latter disorder, although this has not been evaluated specifically in randomized clinical trials. A methodical evaluation of symptoms is recommended in order to distinguish these headaches from tension-type headaches and to treat them appropriately.

It is not clear whether tension-type headache that is secondary to migraine headache ('burnt-out' migraine) differs from primary tension-type headaches in their physiopathology and in their response to treatments. For example, two randomized clinical trials have shown sumatriptan to be inefficacious in primary tension-type headaches ([@b21-tcrm-4-1061]; [@b138-tcrm-4-1061]) but their utility in secondary tension-type headaches evolving from migraine is unknown.

Another important unanswered question relates to whether early and intensive drug treatment of migraine headaches changes the probability of a favorable outcome. In another paroxystic neurological disorder, epilepsy, this is an established therapeutic principle, and merits investigation in long-term follow-up studies of patients presenting with and treated for migraine headaches.

Migraine as a syndrome
======================

It is increasingly apparent that migraine is best understood as a syndrome expressed in several different subtypes of underlying disease. These various subtypes differ in their symptom presentation and are also likely to respond better to certain treatments than to others. A major challenge is to identify the most appropriate treatments for each subtype of migraine.

Familial hemiplegic migraine is probably only the first form of familial migraine whose genetic basis has been elucidated. This form of migraine headache can be considered a channelopathy in which symptoms arise due to a change in the gating kinetics of P/Q type calcium channels brought about by the mutations ([@b113-tcrm-4-1061], [@b114-tcrm-4-1061]). The consequence of this may be an impairment of local GAB-Aergic inhibitory circuits ([@b25-tcrm-4-1061]). It may also be possible to define subtypes of migraine headache based on differences in precipitating factors. First of all, stress-induced headache, mediated by an adrenergic mechanism may be a specific migraine subtype. Stress is the most frequently cited precipitating factor and related to a particular pattern of physiological activation, namely activation of the hypothalamo-pituitary-adenocortical axis and increased sympathetic tone. This may lead to increased vasoconstrictor tone in the cerebral vasculature and thus sensitize individuals to migraine headache.

Mood and sleep disturbances are also common precipitating factors for migraine and these are associated with the central serotonergic system. Another group of precipitating factors relates to sensory stimuli such as particular smells (tobacco or perfume) or foodstuffs (cheese, alcohol, chocolate) and these may also implicate serotonergic mechanisms.

Menstrual migraine provides an example of a form of migraine with a specific precipitating factor, pathogenesis and treatment. Around half of women with migraine report menstruation to be a precipitating factor ([@b91-tcrm-4-1061]; [@b256-tcrm-4-1061]) and the frequency of migraine attacks varies over the reproductive cycle ([@b85-tcrm-4-1061]). A recent large prospective survey in a population of 153 women with migraine ([@b150-tcrm-4-1061]) identified a relative risk of migraine headache of 1.7 in the two days preceding menstruation and of 2.3 in the first three days of menstruation compared to all other times of the cycle. Menstrual migraine attacks have been reported to be of longer duration and to be more incapacitating than non-menstrual migraine ([@b32-tcrm-4-1061]; [@b84-tcrm-4-1061]).

In women with 'pure' menstrual migraine (ie, those who only have headache attacks at the onset of menstruation and not at other times of the cycle), the onset of headache has been associated with rapidly falling plasma concentrations of estrogen ([@b220-tcrm-4-1061]). Indeed, women with menstrual migraine show larger swings in estrogen levels across the menstrual cycle than did women without menstrual migraine ([@b64-tcrm-4-1061]). Estrogen challenge experiments have shown that migraine can be precipitated following artificial elevations of plasma estrogen levels both in women with active menstrual migraine ([@b221-tcrm-4-1061]) and in post-menopausal women with antecedents of menstrual migraine ([@b132-tcrm-4-1061]; [@b65-tcrm-4-1061]). This hypothesis is also supported by the observation that women taking oral contraceptives often experience headache during the estrogen-free week and by reports of emergent migraine in women interrupting hormone replacement therapy ([@b150-tcrm-4-1061]). Exactly how fluctuations in estrogen levels trigger headache is, on the other hand, far from clear. Estrogens have a number of effects on the nervous system involving both genomic actions and direct effects on neuronal excitability ([@b166-tcrm-4-1061]). These latter may sensitize the nervous system to cortical spreading depression or modify gating of nociceptive stimuli in the trigeminal nucleus. Studies in experimental animals have provided evidence for a change in the sensitivity of the GABA~A~ receptor over the course of the estrous cycle ([@b26-tcrm-4-1061]; [@b42-tcrm-4-1061]). It should also be pointed out that estrogens have direct effects on the cerebral vasculature ([@b141-tcrm-4-1061]) which may also contribute to the occurrence of migraine headaches. Menstrual migraine can be treated not only with headache medication active in all types of migraine, but also with specific hormonal treatments aimed at attenuating estrogen withdrawal ([@b142-tcrm-4-1061]). These are described in more detail below.

Finally, certain otherwise typical pulsatile migraine headaches may share features typical of tension-type headaches such as a sensation of muscular pressure or tension, and represent a mixed headache type. These headaches generally localise to the posterior occipital cortex and have a high probability of transformation into a chronic headache type. Whether such headaches are a transition stage in the deteriorating course of certain classical migraine headaches or represent a subtype of migraine with a distinct aetiopathology is unclear, but they are frequently associated with muscular diseases like fibromyalgia.

A proposed classification of migraine headaches based on triggering factors is presented in [Figure 2](#f2-tcrm-4-1061){ref-type="fig"}. The case of menstrual migraine, where a specific prophylaxis can be proposed may illustrate a general principle, and it will be interesting to see whether other prophylactic treatments may be particularly effective in *migraineurs* with particular patterns of precipitating factors. For example, beta-blockers such as propranolol, or alpha-blockers such as indoramine may be particularly effective in Type A migraine (as defined in [Figure 2](#f2-tcrm-4-1061){ref-type="fig"}) whereas antiserotonergic drugs such as methysergide, dihydroergotamine or pizotofen may be more effective in Type B migraine. Hormone therapy is clearly useful in Type C (see below), and muscle relaxant and antidepressant drugs like amitriptyline seem effective in Type D, associated with other prophylactic migraine treatments where necessary. Adequately designed randomized clinical trials will be required to test these hypotheses. Of course, in medical practice patients presenting features typical of more than one headache type are frequently encountered. In these cases, the optimal therapeutic strategy may require association of two or three of these drugs.

Acute treatment of migraine headaches
=====================================

Four classes of drug are used as acute treatments for the relief of headache. Nonsteroidal antiinflammatory drugs (NSAIDs) and analgesics represent non-specific headache relief medications and the triptans and ergot alkaloids migraine-specific treatments. NSAIDs are generally preferred to analgesics as non-specific treatments, since the latter drugs have a high perceived risk of leading to the development of chronic medication-overuse headaches ([@b257-tcrm-4-1061]). However, all acute treatments may to a greater or lesser extent lead to medication overuse headache and prophylactic treatments should be used in patients with frequent headaches to reduce headache frequency and thus recourse to acute medication. Triptans have come to supersede ergot alkaloids as specific headache relief treatments in many countries as they are perceived to have superior tolerability and efficacy.

Various treatment strategies for headache relief have been proposed that combine these drug classes in which patients initially take a non-specific treatment and then add a triptan, first-line/second-line strategies in which patients are initially prescribed an NSAID and then switched to a triptan in case of non-response, and stratified care, in which NSAIDs or triptans are differentially prescribed according to headache severity.

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for acute headache relief both as prescription and over-the-counter medication ([@b146-tcrm-4-1061]). Numerous clinical trials of varying quality have been performed with these agents since the 1960's.

Placebo-controlled trials have shown aspirin to be effective in the relief of migraine headache, either used alone ([@b16-tcrm-4-1061]; [@b123-tcrm-4-1061]; [@b151-tcrm-4-1061]; [@b137-tcrm-4-1061]), in combination with metoclopramide ([@b28-tcrm-4-1061]; [@b238-tcrm-4-1061]; [@b92-tcrm-4-1061]) or in combination with paracetamol and caffeine ([@b139-tcrm-4-1061]). Data from placebo-controlled trials suggests efficacy for ibuprofen ([@b111-tcrm-4-1061]; [@b176-tcrm-4-1061]; [@b199-tcrm-4-1061]; [@b109-tcrm-4-1061]; [@b30-tcrm-4-1061]), including two studies in children ([@b87-tcrm-4-1061]; [@b131-tcrm-4-1061]). Diclofenac has proved superior to placebo in several trials ([@b157-tcrm-4-1061]; [@b35-tcrm-4-1061]; [@b240-tcrm-4-1061]; [@b188-tcrm-4-1061]). An important advantage of diclofenac appears to be its rapidity of action. An intramuscular injectable form is also available and been shown to provide rapid headache relief ([@b106-tcrm-4-1061]; [@b12-tcrm-4-1061]). Ketoprofen has been compared to placebo in a larger study using a standard oral formulation ([@b43-tcrm-4-1061]). This study demonstrated superior efficacy for ketoprofen.

Comparative trials with triptans have been performed for oral aspirin compared to oral sumatriptan ([@b47-tcrm-4-1061]), oral aspirin and metoclopramide compared to oral sumatriptan ([@b241-tcrm-4-1061]; [@b238-tcrm-4-1061]), intravenous aspirin compared to subcutaneous sumatriptan ([@b45-tcrm-4-1061]), oral aspirin and metoclopramide compared to oral zolmitriptan ([@b79-tcrm-4-1061]), oral ibuprofen compared to oral sumatriptan ([@b47-tcrm-4-1061]), oral diclofenac versus oral sumatriptan ([@b240-tcrm-4-1061]), oral naproxen versus oral naratriptan ([@b234-tcrm-4-1061]), oral tolfenamic acid versus oral sumatriptan ([@b174-tcrm-4-1061]) and oral ketoprofen versus oral zolmitriptan ([@b43-tcrm-4-1061]). With the exception of the asprin/zolmitriptan and noproxen/naratriptan studies, all these trials showed comparable efficacy for the NSAID and the triptan in most, if not all, endpoints. [Figure 3](#f3-tcrm-4-1061){ref-type="fig"} presents data on headache relief at two hours from the ketoprofen/zolmitriptan study. Given the comparable efficacy of NSAIDs to triptans and the considerably lower cost of the latter, many treatment guidelines suggest the use of an NSAID as first-line treatment for migraine headache.

Triptans
--------

The introduction of the triptans as specific treatments for migraine headache represented an important breakthrough as these drugs were both more efficacious and better tolerated than previously available drugs (ergot alkaloids). The first demonstration of the potential benefit of triptans came from an open-label proof-of-concept study published in 1988 ([@b51-tcrm-4-1061]), subsequently confirmed in two pivotal randomized controlled trials ([@b63-tcrm-4-1061]). Sumatriptan was first made available as an injectable subcutaneous formulation in 1992 and subsequently as oral tablets and as a nasal spray. Since the introduction of sumatriptan, six other members of this class have been made available. These are zolmitriptan, naratriptan, rizatriptan, eletriptan, frovatriptan and almotriptan. All triptans are 5-HT~1B/D~ serotonin receptor agonists, acting in the cerebral vasculature to promote vasoconstriction and prevent the release of local vasoactive peptides responsible for inflammation and generation of the pain stimulus ([@b68-tcrm-4-1061]). Clinically, triptans have been shown to provide rapid, effective and sustained pain relief and a reduction in the intensity or duration of associated symptoms.

A meta-analysis has been performed concerning 53 clinical trials with these triptans used orally for the acute treatment of migraine ([@b67-tcrm-4-1061]). This concluded that between 40% and 70% of patients treated with a triptan experienced a significant reduction in pain severity after two hours, whereas between 10% and 25% are pain-free and remain pain-free for up to 24 hours. In terms of tolerability, naratriptan and almotriptan were associated with the lowest numbers of treatment-emergent adverse events. Dose-response relationships were observed for all triptans that had been evaluated at multiple doses. Very similar conclusions were drawn from a second meta-analysis evaluating 54 clinical trials which determined efficacy in terms of numbers-needeed-to-treat ([@b179-tcrm-4-1061]). Another meta-analysis of 27 trials also used the numbers-needed-to-treat approach to assess cost-effectiveness, and found almotriptan to be the most cost-effective within the US healthcare system ([@b2-tcrm-4-1061]). This has also been the conclusion of a systematic review of pharmacoeconomic studies with the triptans ([@b143-tcrm-4-1061]). However, relative cost-effectiveness can vary considerably between different healhcare systems ([@b11-tcrm-4-1061]).

There are a number of factors entering into the choice of a given triptan for acute treatment, From the patient's perspective, complete freedom from pain, rapid onset of action, no recurrence and absence of side effects are the most important criteria ([@b126-tcrm-4-1061]). The TRIPSTAR study ([@b82-tcrm-4-1061]; [@b136-tcrm-4-1061]) has attempted to categorise efficacy and tolerability attributes of triptans from extensive structured interviews with physicians and *migraineurs*. In a second step, individual drugs could be matched to this model. On the basis of such analyses, a stepwise heierarchy for the treatment of acute migraine with triptans can be proposed ([Figure 4](#f4-tcrm-4-1061){ref-type="fig"}). The best-tolerated drugs should be used (almotriptan, frovatriptan or naratriptan) as a first-line therapy. If these do not provide an adequate response, one of the other oral triptans should be tried. In case of continued treatment resistance, a nasal spray or injectable preparation should be proposed; This form is also proposed as first line in children.

Prophylaxis of migraine
=======================

Migraine prophylaxis should be considered when acute treatment is insufficient, either due to the severity of the headache disorder or to the ineffectiveness of treatment. Effective prophylaxis of migraine decreases recourse to acute treatment, thus reducing the risk of transformation to chronic headache and also decreases overall healthcare resource utilisation ([@b214-tcrm-4-1061]). Guidelines proposed by the American College of Physicians ([@b217-tcrm-4-1061]) recommend that prophylaxis be initiated in patients with two or more migraine headaches per month that produce disability lasting three or more days per month, contraindications or non-response to acute treatment, the use of relief medication more than twice a week or who present with certain specif*ie*d atypical migraine disorders. Broadly similar recommendations have been published in a number of other national guidelines from, for example, Germany ([@b46-tcrm-4-1061]), the United Kingdom ([@b53-tcrm-4-1061]) and France ([@b80-tcrm-4-1061]).

The medication classes available for the prophylactic treatment of migraine are presented in [Table 1](#t1-tcrm-4-1061){ref-type="table"}. The specific prophylactic agents act by a variety of pharmacological mechanisms, and a large number of molecules have been evaluated in clinical trials of varying quality. A review of all these trials prepared by the Quality Standards Subcommittee of the American Academy of Neurology, however, identified only four agents for which there was strong evidence of high efficacy in the prophylaxis of migraine ([@b211-tcrm-4-1061]). These four drugs were propranolol, timolol, amitriptyline and valproate.

Beta-blockers
-------------

β-Blockers represent the oldest, widest used and best-documented prophylactic treatment for migraine. The utility of propranolol was first identified quite serendipitously in 1972 ([@b250-tcrm-4-1061]) and since then has been the object of numerous clinical trials. A meta-analysis performed in 1991 of studies including 2403 patients included in placebo-controlled clinical trials reported a reduction of 44% in the frequency of headaches in patients receiving propranolol compared to 16% in the placebo group ([@b95-tcrm-4-1061]). A more recent evidence-based review performed for the Cochrane Collaboration ([@b134-tcrm-4-1061]) extending the analysis to over five thousand patients included in 58 trials confirmed the superiority of proranolol to placebo in the prophylaxis of migraine. No clear dose-response relationship is observed with propranolol, necessitating up-titration of the dose until an adequate therapeutic response is observed. In most patients, this is achieved at a dose of 120--240 mg per day ([@b5-tcrm-4-1061]). Propranolol is considered to be the reference prophylactic treatment for migraine. Other β-blockers which have demonstrated superior efficacy for migraine prophylaxis compared to placebo include metoprolol ([@b102-tcrm-4-1061]; [@b229-tcrm-4-1061]), timolol ([@b239-tcrm-4-1061]; [@b230-tcrm-4-1061]), altenolol ([@b71-tcrm-4-1061]; [@b100-tcrm-4-1061]) and nadolol ([@b75-tcrm-4-1061]). Comparable efficacy to propranolol has been shown for all four of these drugs ([@b103-tcrm-4-1061]; [@b181-tcrm-4-1061]; [@b239-tcrm-4-1061]; [@b232-tcrm-4-1061]; [@b198-tcrm-4-1061]; [@b235-tcrm-4-1061]). On the other hand, β-blockers with partial agonist activity such as alprenolol ([@b60-tcrm-4-1061]) or oxprenolol ([@b61-tcrm-4-1061]), have not been shown to be beneficial.

The most common side-effects observed with β-blockers include nausea, dizziness, fatigue, depression and insomnia, although these are generally not severe and do not lead to treatment discontinuation. In the meta-analysis of trials with propranolol ([@b95-tcrm-4-1061]), the rate of study discontinuation for whatever reason was one in six.

Clonidine and other drugs acting at adrenoceptors
-------------------------------------------------

There have been sixteen controlled clinical trials of clonidine for the prophylaxis of migraine. Some of these have found small but significant treatment effects, but most have not ([@b211-tcrm-4-1061]). Two comparative studies suggest that clonidine is less efficacious than β-blockers ([@b107-tcrm-4-1061]; [@b144-tcrm-4-1061]).

Antiserotoninergic drugs
------------------------

A number of small, relatively old clinical trials tested dihydroergotamine in the prophylaxis of migraine ([@b14-tcrm-4-1061]; [@b17-tcrm-4-1061]; [@b125-tcrm-4-1061]; [@b156-tcrm-4-1061]; [@b177-tcrm-4-1061]; [@b190-tcrm-4-1061]). However, a recent randomized, parallel group study versus placebo in 363 patients ([@b191-tcrm-4-1061]) which used a rigorous design following current clinical trial guidelines ([@b237-tcrm-4-1061]) did not reveal a statistically significant difference between the two treatments on the primary outcome measure (headache frequency), although differences in favor of dihydroergotamine were observed for several of the secondary efficacy measures evaluated in the study. In spite of the paucity of evidence, dihydroergotamine is one of the treatment frequently used for the prevention of migraine, for example in France ([@b127-tcrm-4-1061]).

Concerning other ergot derivatives, three cross-over studies ([@b72-tcrm-4-1061]; [@b24-tcrm-4-1061]; [@b168-tcrm-4-1061]) have compared dihydroergocryptine to other prophylactic treatments (propranolol, flunarizine and dihydroergotamine). These studies all concluded that the drug may reduce headache frequency, but the absence of a comparison with a placebo group makes these studies difficult to interpret.

Methysergide is a semi-synthetic derivative of ergot alkaloids that is a relatively selective antagonist at 5-HT2 serotonin receptors. Methysergide was developed for the treatment of migraine in 1959 and the four clinical trials that demonstrated superior efficacy to placebo were performed in the 1960's ([@b121-tcrm-4-1061]; [@b207-tcrm-4-1061]; [@b187-tcrm-4-1061]; [@b197-tcrm-4-1061]). More recently, comparative studies have been performed with propranolol ([@b225-tcrm-4-1061]), flunarizine ([@b226-tcrm-4-1061]) and 5-hydroxytryptophan ([@b242-tcrm-4-1061]). However, methysergide has severally potentially serious side-effects, notably retroperitoneal or retropleural fibrosis ([@b62-tcrm-4-1061]). This is generally associated with long-term, uninterrupted administration and occurs in around one out of every five thousand treated patients. For this reason, methysergide is only recommended for severe migraine that has not responded to other prophylactic treatments ([@b210-tcrm-4-1061]). When methysergide is used, the drug should be discontinued for three to four weeks after every six months of treatment.

Pizotifen (BC105, pizotyline) is extensively used in Europe as a prophylactic treatment for migraine. This serotonin receptor antagonist has been evaluated in several randomized, double-blind studies and shown to be superior to placebo for the prevention of migraine and to reduce utilisation of acute headache relief medication ([@b197-tcrm-4-1061]; [@b183-tcrm-4-1061]; [@b10-tcrm-4-1061]). Head-to-head comparisons has shown its efficacy to be similar to that of the β-blocker metoprolol ([@b246-tcrm-4-1061]). Pizotifen has also been demonstrated to be useful for the treatment of paediatric migraine in a small placebo-controlled study ([@b81-tcrm-4-1061]). Like other 5-HT~2~ receptor antagonists, use of pizotifen is associated with significant weight gain, and treatment discontinuation rates for side-effects are high.

Other 5-HT receptor antagonists that have been evaluated in the prevention of migraine include cyproheptadine, lisuride, oxeterone, iprazochrome, 5-hydroxytryptophan (oxitriptan) and tropisetron. With the exception of tropisetron, these agents are antagonists at 5-HT~2~ receptors, although most of them are relatively aspecific and also act at other mono-amine receptors or ion channels. Cyproheptadine has been found to decrease the frequency of migraine attacks in a small early study ([@b120-tcrm-4-1061]) and has subsequently become widely-used for prevention of migraine headaches in children ([@b13-tcrm-4-1061]). Quite recently, a randomized, double-blind trial compared treatment with placebo, cyproheptadine, propranolol and the combination of the two active drugs ([@b194-tcrm-4-1061]). Not only did this study confirm the benefit offered by cyproheptadine compared to placebo, but also indicated that the association of the two drugs resulted in a larger reduction in headache frequency than did the use of either drug alone. Lisuride was evaluated in two double-blind, placebo-controlled clinical trials ([@b223-tcrm-4-1061]; [@b94-tcrm-4-1061]). Interest in oxeterone stems from four small, double-blind studies performed in Switzerland in the late '70s ([@b37-tcrm-4-1061]; [@b249-tcrm-4-1061]; [@b57-tcrm-4-1061]; [@b70-tcrm-4-1061]). Two randomized, placebo-controlled, double-blind studies of iprazochrome found the drug to be superior to placebo for the prevention of migraine ([@b112-tcrm-4-1061]; [@b183-tcrm-4-1061]); in the first of these, pizotifen was also studied and found to be more effective than iprazochrome. Placebo-controlled studies with 5-hydroxytryptophan have failed to provide convincing evidence of efficacy ([@b36-tcrm-4-1061]; [@b200-tcrm-4-1061]) and comparative studies with methysergide ([@b242-tcrm-4-1061]) and propranolol ([@b154-tcrm-4-1061]) have found 5-hydroxytryptophan to be less effective than these two drugs. Two large, randomized, double-blind, placebo-controlled trials with the 5-HT~3~ receptor antagonist tropisetron have yielded inconclusive results ([@b69-tcrm-4-1061]).

Calcium channel blockers
------------------------

Calcium channel blocking drugs have evoked much interest in the prophylactic treatment of migraine due to their vasodilator effects in the cerebral vasculature ([@b172-tcrm-4-1061]). However, the only such drug that has demonstrated unequivocal efficacy is flunarizine, and it is debatable whether this property is related to calcium channel blockade at all. It has been suggested that a neuronal rather than a vascular action underlies its beneficial effects in migraine ([@b180-tcrm-4-1061]). This drug has been evaluated in nine placebo-controlled clinical trials, although several of these are small or of poor quality. A meta-analysis of the most robust of these trials ([@b195-tcrm-4-1061]) concluded that treatment flunarizine resulted in a greater reduction in headache frequency than placebo. Comparative trials have generally demonstrated a similar effect size as that obtained with propranolol ([@b147-tcrm-4-1061]; [@b148-tcrm-4-1061]; [@b77-tcrm-4-1061]; [@b44-tcrm-4-1061]) or metoprolol ([@b86-tcrm-4-1061]; [@b224-tcrm-4-1061]). One small study which investigated combination therapy with propranolol and flunarizine failed to demonstrate superior efficacy for the combination compared with monotherpay with either drug alone ([@b15-tcrm-4-1061]).

The side effects described for treatment with flunarizine are somnolence, weight gain, and, in less frequently, depression. Treatment discontinuation rates due to side-effects have been high in many of the clinical trials. Due to the relatively poor side-effect profile of flunarizine compared to β-blockers, the use of this drug should be reserved for second-line treatment ([@b172-tcrm-4-1061]). Dotarizine is an analogue of flunarizine which has showed preliminary evidence of efficacy for the prophylaxis of migraine ([@b76-tcrm-4-1061]).

Concerning other classes of calcium channel blocker, studies with dihydropyridines have been inconclusive ([@b172-tcrm-4-1061]). Nifedipine was found to offer no benefit over placebo in two randomized, double-blind clinical trials ([@b165-tcrm-4-1061]; [@b208-tcrm-4-1061]), whereas nicardipine ([@b129-tcrm-4-1061]) was reported to be effective. For nimodipine, two positive ([@b78-tcrm-4-1061]; [@b88-tcrm-4-1061]), and three negative ([@b8-tcrm-4-1061]; [@b169-tcrm-4-1061], [@b170-tcrm-4-1061]) placebo-controlled studies have been reported. Study sizes were rather small in all cases. Preliminary evidence for the efficacy of verapamil has come from three small placebo-controlled trials, none of which included more than twenty-five patients ([@b218-tcrm-4-1061]). Diltiazem has not been evaluated in randomized, double-blind controlled studies. The most recently evaluated calcium channel blocker is cyclandelate, for which three placebo-controlled trials have been performed, two of which included over 200 patients ([@b48-tcrm-4-1061]; [@b49-tcrm-4-1061]) and did not demonstrate superior efficacy to placebo in preventing headaches. The third, smaller (n = 25) study did find cyclandelate to be more efficacious than placebo ([@b216-tcrm-4-1061]).

Antiepileptic drugs
-------------------

Although interest in the potential of antiepileptic drugs for the treatment of migraine headache goes back over thirty years ([@b196-tcrm-4-1061]), there has been a renewal of interest in such drugs over the last decade. Most of the large randomized clinical trials in migraine prophylaxis which have used current standards of clinical trial methodology (IHSCCT 1991) have concerned this class of drug, which represents the principal innovation in the field for over twenty-five years. Antiepileptic drugs reduce neuronal excitability and thus reduce the cortical spreading depression that is believed to be an early event in the development of migraine headache ([@b251-tcrm-4-1061]). A number of studies using transcranial magnetic stimulation or magnetoencephalography ([@b18-tcrm-4-1061]; [@b173-tcrm-4-1061]) have shown that antiepileptic drugs do effectively reduce cortical hyper-excitability in patients with migraine.

A number of antiepileptic drugs was tested over the past twenty years ([@b118-tcrm-4-1061]; [@b212-tcrm-4-1061]; [@b29-tcrm-4-1061]; [@b254-tcrm-4-1061]). These include valproate, topiramate, gabapentin, lamotrigine, carbamazepine, clonazepam, tiagabine, leviracetam and zonisamide. Recent, large-scale controlled trials are however limited to the first four drugs, and only valproate and topiramate have been approved for the prophylaxis of acute migraine in some countries. Studies performed with tiagabine ([@b55-tcrm-4-1061]; [@b73-tcrm-4-1061]), levetiracetam ([@b54-tcrm-4-1061]; [@b115-tcrm-4-1061]) and zonisamide ([@b54-tcrm-4-1061]; [@b116-tcrm-4-1061]) did not include a control group and thus allow no conclusions to be drawn as to their real clinical benefit.

The first clinical trial dates from 1970, when [@b196-tcrm-4-1061] evaluated the efficacy of carbamazepine in a randomized, placebo-controlled, cross over study, and observed an improvement in 84% of patients during treatment with carbamazepine compared to 27% during the placebo phase, and a corresponding reduction in the number of migraine attacks from 186 under placebo to 30 under carbamazepine.

The first study evaluating the efficacy of valproate, and using a placebo-controlled double-blind randomized cross-over design in twenty-nine patients ([@b93-tcrm-4-1061]). Patients received a low dose of valproate (400 mg) for eight weeks. Reduction of the frequency, severity and duration of migraine attacks was observed in 86.2% of the patients studied. A number of subsequent randomized, controlled studies have valproate in the prophylaxis of migraine headache ([@b98-tcrm-4-1061]; [@b163-tcrm-4-1061]; [@b110-tcrm-4-1061]; [@b74-tcrm-4-1061]), and concluded that this drug is an efficacious, well-tolerated and easy-to-use medication. Notably, the findings were replicated in a much larger study including 107 patients and using a parallel-group design ([@b163-tcrm-4-1061]). A reduction of at least 50% in headache frequency compared to baseline was observed in 48% of patients receiving valproate compared to 14% of those receiving placebo. The severity of residual headaches was also reduced in the valproate treatment group. However, there was a higher rate of adverse events and of treatment discontinuation in patients receiving valproate. A dose-ranging study comparing fixed doses of 500 mg, 1000 mg, or 1500 mg with placebo ([@b110-tcrm-4-1061]) showed similar efficacy between all three doses, and recommended that the 500 mg/day dose should be used in most patients. A subsequent study, in which responses were related to plasma levels of valproate, also concluded that for most patients, doses over 600 mg/day would provide no additional benefit over lower doses.

It should be noted that intravenous valproate has also been evaluated in several randomized, controlled studies ([@b58-tcrm-4-1061]; [@b236-tcrm-4-1061]; [@b130-tcrm-4-1061]) for the acute treatment of migraine, following the publication of an extensive uncontrolled case series suggesting the interest of such a treatment ([@b161-tcrm-4-1061]). Although efficacious, it appeared less active than intravenous lysine-acetylsalicylic acid or prochlorperazine. The tolerability and commodity of use of intravenous valproate in this indication are obviously inferior compared to triptans or NSAIDS and this treatment is unlikely to be of widespread use.

Although treatment with valproate is generally well-tolerated, this drug is associated with an elevated teratogenic risk ([@b244-tcrm-4-1061]). In patients with epilepsy, this risk has been estimated in a number of dedicated retrospective and prospective surveys. For example, in a recent analysis of data from the Swedish Medical Birth Registry and the Swedish Registry of Congenital Malformations, the rate of major malformations in neonates exposed to valproate *in utero* was 9.7% compared to 1.0% in the Swedish general population ([@b252-tcrm-4-1061]). There is some evidence that this risk is dose-related, being particularly high with valproate doses over 800--1000 mg/day. In patients with migraine, of whom women of child-bearing age represent the majority, this risk clearly needs to be taken into account in assessing the risks and benefits of treatment with valproate. Unlike what is observed for epilepsy, where this may be the only drug that offers complete seizure freedom, in migraine, valproate is just one of a number of agents that offers a similar level of headache relief.

The most data on the utility of antiepileptic drugs in the prophylaxis of migraine has been obtained for topiramate. The interest of this drug was first suggested in a series of open-label studies ([@b117-tcrm-4-1061]; [@b160-tcrm-4-1061]; [@b205-tcrm-4-1061]; [@b247-tcrm-4-1061]; [@b253-tcrm-4-1061]) and subsequently confirmed in two randomized controlled pilot studies ([@b233-tcrm-4-1061]; [@b59-tcrm-4-1061]).

Two large pivotal randomized Phase III clinical trials were performed and the results used to obtain marketing authorisation for topiramate. These evaluated three doses of topiramate (50 mg/day, 100 mg/day and 200 mg/day) in over 900 adult subjects using an identical design ([@b20-tcrm-4-1061]; [@b213-tcrm-4-1061]). These studies demonstrated a reduction in the monthly frequency of migraine headaches of 30% to 50% following initiation of topiramate treatment ([Figure 5](#f5-tcrm-4-1061){ref-type="fig"}). The effect of topiramate was dose-related and usually was observable within the first month of treatment. Since then, several other randomized, controlled studies have generated data largely consistent with the results of the pivotal studies ([@b215-tcrm-4-1061]; [@b50-tcrm-4-1061]; [@b167-tcrm-4-1061]).

However, a number of potentially serious side-effects are associated with topiramate ([@b101-tcrm-4-1061]), and it is important to consider safety issues carefully before and during treatment of patients with migraine with this antiepileptic drug. Many of these side-effects are related to inhibition of carbonic anhydrase, including metabolic acidosis, formation of kidney stones, acute myopia associated with secondary angle closure glaucoma, paraesthesia and oligohidrosis. In addition, impairments of cognitive function (slowing of thought processes) and fatigue are commonly reported. Topiramate use is also associated with significant weight loss, which may also be detrimental to self-image and quality of life. The incidence of these side-effects appears to be dose-related and can be mitigated by slowly titrating the dose upwards.

Two randomized, placebo-controlled studies have assessed the efficacy and safety of gabapentin in the prophylaxis of migraine. One study evaluated doses of 900 mg/day to 2400 mg/day and included 143 subjects ([@b162-tcrm-4-1061]), whilst the other evaluated a fixed dose of 1200 mg/day in 63 subjects ([@b41-tcrm-4-1061]). The larger study demonstrated a higher proportion of patients achieving a reduction in the monthly migraine rate of at least 50% in the gabapentin-treated patients compared to those receiving placebo, and a significant reduction in the frequency and severity of migraine headaches was reported in the smaller study. Nonetheless, somnolence and dizziness were observed in a significant minority of patients. A subsequent randomized, open-label study found essentially similar findings ([@b99-tcrm-4-1061]).

Lamotrigine has been studies in three open-label studies ([@b34-tcrm-4-1061]; [@b119-tcrm-4-1061]; [@b185-tcrm-4-1061]) and one randomized, placebo controlled study ([@b228-tcrm-4-1061]). Although the open-label studies suggested that lamotrigine could be of benefit, particularly in relieving aura, the placebo-controlled study, which included 110 patients, found no evidence that the efficacy of lamotrigine was superior to placebo.

Clonazepam has been evaluated in a small, randomized, placebo-controlled double-blind, cross-over study ([@b231-tcrm-4-1061]). This alternated four-week treatment-free run-in periods with four-week treatment periods where the patients received placebo, clonazepam 1 mg or clonazepam 2 mg. A significant reduction in headache frequency compared to the run-in period was observed for the two clonazepam-treatment periods but not for the placebo period.

Compared with β-blockers, randomized clinical trials of valproate ([@b105-tcrm-4-1061]) and topiramate ([@b50-tcrm-4-1061]) have shown these two drugs to have similar efficacy to propranolol, although the β-blocker was better tolerated. Due to this difference in tolerability, antiepileptic drugs should be considered principally as second-line treatments in patients who have failed to respond adequately to β-blockers. There is little information on the utility of combining antiepileptic drugs and β-blockers. An open-label study which evaluated the combination of propranolol or nadolol with valproate in 52 subjects who had failed to respond to the individual drugs in monotherapy ([@b186-tcrm-4-1061]). This study demonstrated that over half the treated subjects responded to the combination treatment. A second open-label study investigated add-on treatment with topiramate in patients who responded inadequately to current prophylactic treatment, principally with propranolol or flunarizine ([@b155-tcrm-4-1061]). Again, headache frequency decreased after initiation of combination treatment. These interesting observations deserve confirmation in randomized, double-blind studies.

Antidepressants
---------------

The utility of certain antidepressants for the prophylaxis of migraine dates from the only 1970s ([@b83-tcrm-4-1061]). The most widely studied antidepressant is amitriptyline and this agent appears to be the most efficacious ([@b31-tcrm-4-1061]). It is possible that amitriptyline is active in the prophylaxis of migraine by virtue of an action at voltage-sensitive ion channels controlling neuronal excitability. However, this drug causes sedation which may not be desirable in patients taking this drug every day for migraine prophylaxis. In this respect, other antidepressants with a more acceptable side-effect profile may be preferred. For example, venlafaxine was shown to be reduce headache frequency in a retrospective case series ([@b3-tcrm-4-1061]) and has since shown similar efficacy to amitriptyline and superior efficacy to placebo in two recent randomized, double-blind studies ([@b22-tcrm-4-1061]; [@b184-tcrm-4-1061]).

Other older antidepressants for which there is some evidence for efficacy in the prophylaxis of migraine include clomipramine ([@b178-tcrm-4-1061]; [@b124-tcrm-4-1061]), opipramol ([@b97-tcrm-4-1061]) and mianserin ([@b171-tcrm-4-1061]). However, these relatively old studies generally included small numbers of patients, were not always double-blinded, and did not use the design and outcome criteria currently recommended for randomized clinical trials in migraine ([@b237-tcrm-4-1061]).

The utility of selective-serotonin reuptake inhibitors in the prophylaxis of migraine is much less clear. Early studies performed in the 1980's in Scandinavia failed to demonstrate clear efficacy for femoxitine ([@b6-tcrm-4-1061]; [@b255-tcrm-4-1061]; [@b104-tcrm-4-1061]; [@b182-tcrm-4-1061]) and more recent studies with sertraline ([@b122-tcrm-4-1061]) and citalopram have also been disappointing ([@b193-tcrm-4-1061]). On the other hand, there is some weak evidence for the efficacy of fluvoxamine ([@b9-tcrm-4-1061]) and fluoxetine ([@b4-tcrm-4-1061]; [@b201-tcrm-4-1061]; [@b227-tcrm-4-1061]; [@b33-tcrm-4-1061]).

Of particular interest is the use of amitriptyline, and potentially other antidepressants, in the treatment of chronic daily headache. A meta-analysis of thirty-eight clinical trials ([@b243-tcrm-4-1061]) concluded that all classes of antidepressant drug evaluated (tricyclics, selective serotonin reuptake inhibitors and serotonin receptor antagonists) were all effective in reducing the frequency of both migraine-type and tension-type chronic daily headaches with an effective size that was considered as large. This allowed a reduction in the use of analgesics as headache relief medication. Since analgesic use is considered to be an important factor in the development and maintenance of chronic headaches, and a major determinant of poor prognosis, prophylaxis with antidepressants may improve clinical outcome over the long-term as well as reducing headache frequency in the short-term.

Hormone therapy for menstrual migraine
--------------------------------------

Oral contraception with progestins can be effective in reducing the frequency of menstrual migraine headaches ([@b19-tcrm-4-1061]; [@b222-tcrm-4-1061]), presumably by suppression of the menstrual cycle. However, oral contraceptive regimens using continuous progestin exposure seem interesting but are no longer widely used, and current standard oral contraceptives have not been found to be particularly efficacious ([@b209-tcrm-4-1061]). Use of long-acting estrogen preparations such as gels ([@b39-tcrm-4-1061]; [@b40-tcrm-4-1061]; [@b153-tcrm-4-1061]; [@b152-tcrm-4-1061]) or patches ([@b38-tcrm-4-1061]; [@b189-tcrm-4-1061]; [@b192-tcrm-4-1061]) have also been reported to be effective for migraine prophylaxis and may be more suitable formulations in this indication. These estrogens initiated at the end of the luteal phase and maintained until the end of the menstrual period compensate for the rapid fall of endogenous estrogen concentrations that is thought to precipitate migraine headaches. Two small clinical trials of phytoestrogens ([@b23-tcrm-4-1061]; [@b66-tcrm-4-1061]) suggested that these agents may also be effective in the treatment of menstrual migraine.

Conclusions
===========

Advances in our understanding of the pathophysiology of migraine have resulted in important breakthroughs in treatment. Notably, understanding of the role of serotonin in the cerebrovascular circulation led to the development of triptans for the acute relief of migraine headaches, and the identification of cortical spreading depression as an early central event associated wih migraine has brought renewed interest in antiepileptic drugs for migraine prophylaxis.

Nevertheless, several important questions remain. Firstly, while it is increasingly recognized that migraine is not a single disease but rather a syndrome that can manifest itself in a variety of pathological conditions, the consequences of this for treatment are not understood. Clinical research needs to be devoted to identifying which sort of patients benefit best from which treatments, particularly in the field of prophylaxis. One possible approach that merits exploration is to try and match prophylactic treatments to particular patterns of precipitating factors, as has already proved successful for the treatment of menstrual migraine In this respect, the proposal of four types of migraine (adrenergic, serotoninergic, menstrual, and muscular) may contribute to the optimisation of migraine prophylaxis.

The interest of stratifying treatment strategies by headache severity is also at an early stage. Studies such as DISC ([@b140-tcrm-4-1061]; [@b206-tcrm-4-1061]) suggest that this could be a useful approach, but treatment stratification remains under-exploited in routine care of patients with migraine. Further prospective studies would help characterising patient severity groups that would benefit from particular strategies.

Treatment resistance is frequent with both acute and prophylactic treatments of migraine. Even with triptans, probably the most effective class of antimigraine drug, up to one-third of patients fail to respond adequately. The reasons underlying treatment resistance need to be better understood, and strategies identified to avoid serial treatment failures when the patient first comes to the clinic.

Moreover, there is a lack of information on the benefit of combination treatment using different drug classes. This approach may be of particular use in patients with more severe hedaches and in those showing mixed headache types. In this respect, and bearing in mind potential artefacts due to the open-label design of the study, the results of the combination study with propranolol and valproate imply that these two agents can be used in association to provide greater efficacy in particular patients. Further studies such as this using a randomized, double-blind design are required to provide the data necessary to orientate treatment decisions about combinations of migraine prophylaxis agents.

Finally, little is known about long-term outcome in treated migraine. It is possible that appropriate early prophylaxis may modify the long-term course of the disease and avoid late complications, as has been shown, for example, in another paroxystic neurological condition, epilepsy. This is particularly relevant for antiepileptic drugs that are thought to be of benefit in migraine by an action on cortical excitability. If this is the case, then early aggressive migraine prophylaxis may be merited. Although medication overuse can be a predisposing factor to developing a chronic headache syndrome, risk thresholds remain poorly quantified, particularly for specific acute migraine treatments such as the triptans.

Although migraine is much better defined than it was twenty years ago, and more efficacious and better tolerated treatments are on offer, there is still a long way to go before we can provide patients with individualized and rational long-term therapeutic management strategies that take into account the heterogeneity of the migraine condition and its variable clinical course.
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![Relief of migraine attack in 235 patients included in a comparative study of ketoprofen and zolmitriptan using a cross-over design ([@b43-tcrm-4-1061]). Data are given as the percentage of the total number of attacks that were reduced in severity to mild or absent at two hours. Treatment groups are placebo (P), ketoprofen 75 mg (K75), ketoprofen 150 mg (K) and zolmitriptan 2.5 mg (Z). The asterisk indicates a significant difference (p \< 0.0001; GEE model) between the bracketed groups.](tcrm-4-1061f3){#f3-tcrm-4-1061}

![Treatment hierarchy for the acute treatment of migraine with triptans.](tcrm-4-1061f4){#f4-tcrm-4-1061}

![Efficacy of topiramate in the prophylaxis of migraine. Three different doses of topiramate (TPM; 50 mg/day, 100 mg/day, and 200 mg/day) are compared with placebo (Pbo). Data represent the change in monthly migraine frequency compared to a pre-treatment baseline period. The asterisks indicate a statistically significant difference from placebo (\*p \< 0.01; \*\*p \< 001). Data are taken from [@b20-tcrm-4-1061] (grey columns) and [@b213-tcrm-4-1061] (black columns).](tcrm-4-1061f5){#f5-tcrm-4-1061}

###### 

Prophylactic treatments for migraine

  ---------------------------------- ------------------------------------ ----------------------------
  β-Blockers                         Propranolol, metoprolol              First-line treatment
  α-Adrenergic drugs                 Indoramine, clonidine                Evidence for efficacy weak
  Antiserotonergic drugs             Methysergide, pizotifen, oxeterone   
  Certain calcium channel blockers   Flunarizine                          Second-line treatment
  Certain antidepressants            Amitriptyline                        
  Certain antiepileptic drugs        Valproate, topiramate                Second-line treatment
  Ergot alkaloids                    Dihydroergotamine                    
  Estrogens                          Estrodiol gel                        For menstrual migraine
  ---------------------------------- ------------------------------------ ----------------------------
